Thermo Fisher Scientific Inc. will showcase its broad diagnostics portfolio and host a series of customer-led workshops and presentations that highlight industry developments and the company’s latest innovations during the Association for Diagnostics & Laboratory Medicine Conference (ADLM) from July 28 to August 1, 2024, in Chicago, Ill. The company’s conference booth (#2213) has been designed as a “Story Tunnel” to lead visitors on a journey of research and clinical solutions impacting patient care across oncology, infectious disease, women’s health, toxicology, allergy and autoimmune diseases, and transplant and protein diagnostics.

This press release features multimedia. View the full release here: Business Wire

Activities in booth #2213 highlight comprehensive diagnostics solutions to help effectively assess clinical risk and diagnose disease, advance precision medicine, and further clinical research. (Photo: Business Wire)

“As the demands of the healthcare industry evolve, we continuously collaborate with our customers to provide advanced and reliable diagnostics solutions to help accelerate the development of new therapies and disease identification, ultimately supporting more informed treatment decisions for patients,” said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. “With our product innovation, we’re also strengthening our distribution channels to ensure our leading-edge solutions are accessible to those who need them. We are driven by our Mission to enable our customers to make the world healthier, cleaner and safer, supporting our customers in the moments that matter most.”

Advancements in Oncology

Supporting innovation in protein diagnostics, Thermo Fisher will demonstrate the Optilite® Analyzer and provide an overview of the Freelite® assays, which received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to evaluate monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma.

Integration of liquid chromatography mass spectrometry (LC-MS) into healthcare settings continues with the recent launch of the Thermo Scientific™ Stellar™ mass spectrometer, an LC-MS solution that combines fast throughput and high sensitivity to advance clinical research. PrognomiQ, a diagnostic company transforming cancer detection and early treatment using multi-omics, will present their progress from plasma proteomics discovery to translated clinical assay on July 31, 2024, from 7:00 – 8:00 AM CT at the Hyatt Regency, Grant Park AB.

Dr. Allison Eck, director of Pathology and Laboratory Medicine at Doylestown Health, will discuss the adoption of next-generation sequencing (NGS) in local pathology departments in her presentation on July 31, 2024, from 11:00 – 11:20 AM CT in Exhibit Hall Theater #2.

Enabling Maternal and Women’s Health

Recognized as one of TIME’s best inventions, Thermo Fisher’s preeclampsia immunoassays will be featured in the ‘Story Tunnel’ booth, showcasing how novel biomarkers are impacting treatment decisions for mothers and unborn children. Dr. Sarosh Rana, professor of Obstetrics and Gynecology and Section Chief of Maternal-Fetal Medicine at the University of Chicago, will share insights on leveraging biomarker-based testing innovations for maternal health.

Infectious Disease and Evolving Regulations

Dr. Stephen Williams, clinical director at Thermo Fisher Scientific, will host a workshop on HIV integrase inhibitor resistance on July 30, 2024, from 7:00 – 8:30 AM CT in North Hall, Room 231. Dr. Michael Broyles, director of medical affairs at Thermo Fisher, will discuss antibiotic stewardship regulations on July 30, 2024, from 12:45 – 1:45 PM CT in Theater #3. Dr. Jennifer Dien Bard, interim chief of Laboratory Medicine and director of Clinical Microbiology and Virology at the Children’s Hospital in Los Angeles, will present on automated, targeted metagenomics NGS for rapid pathogen detection on July 31, 2024, from 11:30 – 11:50 AM CT in Exhibit Hall #2.

Optimizing Autoimmune Diagnostics

Thermo Fisher will present on the automated IFA and EliA assays through a partnership with Aesku Group on July 31, 2024, from 1:00 – 1:20 PM CT in Exhibit Hall #2. These assays, run on Phadia Laboratory Systems, enhance laboratory efficiency and support earlier diagnosis for patients with autoimmune conditions.